The treatment of pulmonary tuberculosis with ‘Dipasic’

Walker, W.C.; Hay, David C.; Stewart, Sheila M.; Crofton, John

doi:10.1016/s0041-3879(57)80179-2

Cited by 7 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found that some patients were treated with dipasic rather than INH. Dipasic is a compound formed by chemical combination between isoniazid and p-aminosalicylic acid (PAS) in equimolecular proportions [ 11 – 13 ]. Studies have reported that dipasic is equivalent to INH alone, rather than two drugs (INH and PAS).…”

Section: Discussionmentioning

confidence: 99%

“…A standardized questionnaire was developed for data collection, which included sex, age at diagnosis of TB, type of case (new, retreatment including relapse, treatment after loss-to-follow-up, and treatment after failure), smear for acid-fast bacilli, culture for M . tuberculosis , drug susceptibility testing, body weight at baseline, date of treatment initiation, type of clinician who initiated treatment (junior vs senior), status of health insurance of patients (with or without), frequency of drugs administered (daily or intermittently), drugs used including INH, RMP, PZA, EMB, SM, rifapentine, rifabutin, 4-drug fixed dose combination (FDC) of HRZE (FDC-HRZE, INH 75mg, RMP 150mg, EMB 400mg, PZA 400 mg), 2-drug FDC of HR (FDC-HR-1, INH 75mg, RMP 300mg; and FDC-HR-2, INH 75mg, RMP 150mg), 2-drug FDC of H and PAS (FDC-HP (dipasic), INH 47.3 mg, PAS 52.7 mg) [ 11 – 13 ], blister pack of HRZE (BP-HRZE, INH 600mg, RMP 600mg, EMB 1250mg, PZA 2000 mg), blister pack of HER (BP-HER, INH 600mg, RMP 600mg, EMB 1250mg), blister pack of HR (BP-HR, INH 600mg, RMP 600mg), ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, kanamycin, amikacin, capreomycin, protionamide, cycloserine, PAS, amoxicillin/clavulanate, clarithromycin, linezolid, clofazimine, as well as frequency and dosage of each drug prescribed. We classify INH, RMP, PZA, EMB, SM, rifapentine, rifabutin, FDC-HRZE, FDC-HR-1, FDC-HR-2, dipasic, BP-HRZE, BP-HER, and BP-HR as first line drugs.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit

Chen

Innes

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectivesChina has a high burden of drug-resistant tuberculosis (TB). As irrational use and inadequate dosing of anti-TB drugs may contribute to the epidemic of drug-resistant TB, we assessed the drug types and dosages prescribed in the treatment of TB cases in a representative sample of health care facilities in Yunnan. MethodsWe applied multistage cluster sampling using probability proportion to size to select 28 counties in Yunnan. Consecutive pulmonary TB patients were enrolled from either the TB centers of Yunnan Center of Disease Control or designated TB hospitals. Outcomes of interest included the regimen used in the treatment of new and retreatment TB patients; and the proportion of patients treated with adequate dosing of anti-TB drugs. Furthermore, we assess whether there has been reduction in the use of fluoroquinolone and second line injectables in Tuberculosis Clinical Centre (TCC) after the training activity in late 2012. ResultsOf 2390 TB patients enrolled, 582 (24.4%) were prescribed second line anti-TB drugs (18.0% in new cases and 60.9% in retreatment cases); 363(15.2%) prescribed a fluoroquinolone. General hospitals (adjusted odds ratio (adjOR) 1.97, 95% confidence interval (CI) 1.47-2.66), retreatment TB cases (adjOR 4.75, 95% CI 3.59-6.27), smear positive cases (adjOR 1.69, 95% CI 1.22-2.33), and extrapulmonary TB (adjOR 2.59, 95% CI 1.66-4.03) were significantly associated with the use of fluoroquinolones. The proportion of patients treated with fluoroquinolones decreased from 41.4% before 2013 to 13.5% after 2013 (adjOR 0.19, 95% CI 0.12-0.28) in TCC. The proportion of patients with correct, under and over dosages of isoniazid was 88.2%, 1.5%, and 10.4%, respectively; of rifampicin was 50.2%, 46.8%, and 2.9%; of pyrazinamide was 67.6%, 31.7% and 0.7%; and of ethambutol was 41.4%, 57.5%, and 1.0%.PLOS ONE | https://doi.org/10.1371/journal.pone

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Prescription practice of anti-tuberculosis drugs in Yunnan, China: A clinical audit

Chen

Innes

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…I n another bacteriological study, Wilde (7) showed that thc combination was not superior to a physical mixture, but with guinea pigs and mice (8) he found the yellow combination was superior to the physical mixture. Walker and co-workers (9) in Scotland, after a clinical evaluation, found no evidence that the isoniazid-PAS combination acts as a compound independent of its isoniazid and PAS content.…”

Section: Discussionmentioning

confidence: 97%

Examination of the Physical Chemical Basis for the Isoniazid- p -Aminosalicylic Acid Combination * *School of Pharmacy, University of Wisconsin, Madison

Reinstein¹,

Higuchi²

1958

Journal of the American Pharmaceutical Association (Scientific

View full text Add to dashboard Cite

“…since its effectiveness is unproved. dipasic because its therapeutic and antibacterial effects are similar to those of isoniazid, and, when given alone as often recommended, isoniazid resistance develops (Walker et al, 1957;Allan et al, 1957;Williams and Prokopowicz, 1958).…”

Section: O12nsmentioning

confidence: 99%